Zydus Q4FY26: ₹1,100cr buyback, margins at 33.7%

Key developments for shareholders

Zydus Lifesciences reported a strong March-quarter performance even as one-off expenses created a gap between reported and adjusted earnings. Alongside the quarterly numbers, the board approved a share buyback of up to ₹1,100 crore and announced a 100% dividend for FY26. The announcements put the stock in focus on Tuesday, May 19, with shares trading higher during the session.

The quarter was marked by faster growth in EBITDA than revenue, leading to margin expansion. At the same time, the company booked a one-time expense linked to a litigation settlement, which affected the reported profit line.

Q4FY26 earnings: reported vs adjusted profit

For Q4FY26, Zydus posted a reported net profit of ₹1,272.5 crore, up 8.7% year-on-year, despite exceptional costs. The company also reported an adjusted net profit of ₹1,592.9 crore, up 15% year-on-year, indicating stronger underlying operating performance when excluding certain exceptional items.

The key driver behind the difference between reported and adjusted profit was a one-time expense of ₹397.5 crore towards the Mirabegron litigation settlement. Separately, the company’s standalone financials included an exceptional item gain of ₹1,068 crore related to impairment in the value of investment in Zydus VTEC Ltd., a wholly owned subsidiary.

Revenue growth and margin expansion

Revenue from operations rose 16.2% year-on-year to ₹7,587 crore from ₹6,528 crore. EBITDA increased 20.2% to ₹2,554 crore from ₹2,125.5 crore, taking the EBITDA margin to 33.7% from 32.6% a year ago. The margin expansion for the quarter was stated at 110 basis points.

Zydus also disclosed that excluding forex gains, EBITDA stood at ₹1,909 crore with a margin of 25.2%. This provided an additional view of operating profitability beyond the headline margin.

Segment highlights: India formulations and consumer wellness

India formulations revenue rose 14% year-on-year to ₹1,752.8 crore from ₹1,537.4 crore. The growth was attributed to chronic therapies and super-speciality segments such as oncology and nephrology. The India business accounted for 24% of consolidated revenue.

Consumer wellness was a standout, rising 61% year-on-year. One report quantified consumer wellness revenues at ₹1,463.3 crore versus ₹908.1 crore in the year-ago quarter, aided by strong international performance and categories such as skin and nutrition.

On the broader business mix, the pharmaceutical business contributed ₹5,643.6 crore, a 4.9% rise year-on-year.

Other operational cues mentioned during the quarter

Beyond India and consumer wellness, the quarter had mixed segment signals in commentary around the results. North America was reported to be down 6% year-on-year, while the intramuscular formulations segment was up around 45%. APIs were described as sluggish, down around 5.5%.

Medtech, described as a newer addition to the business, contributed ₹327.5 crore to the total business and recorded both quarter-on-quarter and year-on-year growth, as per the same commentary.

Buyback: size, price, route, and record date

The board approved a buyback of up to ₹1,100 crore at ₹1,150 per share via the tender offer route. The company plans to repurchase up to 95.65 lakh equity shares (95,65,217 shares). Promoters are expected to participate.

May 29, 2026 has been fixed as the record date to determine shareholder eligibility. The buyback price of ₹1,150 per share was stated to be at a premium of about 16% to the company’s closing price on Monday, May 18, 2026.

Dividend for FY26

Along with the buyback, the company announced a 100% dividend for FY26. Another report specified that a final dividend of ₹1 per equity share has been recommended, subject to shareholder approval.

What the Street expected, and how Zydus performed

According to a CNBC-TV18 poll cited in the reports, the Street had estimated Q4 net profit at ₹997.5 crore and revenue at ₹7,086 crore. Zydus’ reported profit of ₹1,272.5 crore and revenue of ₹7,587 crore were above those estimates.

The same poll had an EBITDA estimate of ₹1,632.6 crore and an expectation for margin at 23%. Zydus reported EBITDA of ₹2,554 crore and a margin of 33.7%, which were also above those expectations.

Stock reaction and broader market context

Zydus shares rose during Tuesday’s session after the results and buyback announcement. One update pegged the stock up 2.80% at ₹1,018.95 at 3:50 pm on BSE, while another noted it trading about 5.3% higher at ₹1,047 after the earnings announcement.

The broader market was slightly lower in the same window, with the Sensex down 0.15% at 75,200 points. The stock was also reported to be up 14% so far in 2026.

Key numbers at a glance

Why this set of announcements matters

The combination of margin expansion and capital return actions is the main takeaway from the disclosures. The quarter showed EBITDA growth outpacing revenue growth, and the company highlighted profitability even after isolating forex gains.

At the same time, the reported vs adjusted profit gap underlined how litigation-related settlements and other exceptional items can influence headline earnings. For investors, the tender buyback structure and the record date are the immediate operational details to track, alongside the shareholder approval process for the final dividend.

Conclusion

Zydus Lifesciences closed Q4FY26 with revenue growth, higher operating profit, and margin expansion, while absorbing a ₹397.5 crore one-time litigation settlement cost. The board’s ₹1,100 crore buyback at ₹1,150 per share and the FY26 100% dividend set the next milestones, with May 29, 2026 as the record date for the buyback.